Healthcare-Associated Infection Prevention Program

The Healthcare-Associated Infection/Antibiotic Resistance (HAI/AR) Prevention Program aims to eliminate and prevent HAIs and AR organisms. ​

Program Goals

  • Identify and contain AR organisms
  • Promote appropriate use of antimicrobials
  • Submit data submission to health care facilities for targeted intervention to decrease HAIs
  • Promote sustainable prevention infrastructure in health care facilities across the state

Objectives

  1. Identify and contain emerging pathogens and antibiotic resistant organisms of interest
  2. Improve outbreak identification, investigation and reporting
  3. Use the CDC National Healthcare Safety Network for surveillance of HAIs
  4. Support implementation of antimicrobial stewardship in health care facilities
  5. Provide education, mentorship and support to infection preventionist in all health care settings
  6. Facilitate evidence-based practices for infection prevention and control in health care settings through education and training, consultation and access to resource materials.

HAN Alert- Candida auris

On May 13, 2021, a Health Alert Network (HAN) communication was issued in Kentucky.  An updated HAN was issued on July 15, 2021. HAN Alert for C. auris ​

Required Reporting-Updated

HAIs and MDROs reporting regulation - 902 KAR 2:020 Reportable disease surveillance

Changes in reporting requirements for all MDROs have been made.

  • Reporting within one business day of:
  • Candida auris with
    • Confirmatory lab evidence (PCR or culture)
    • EPID 250 (fax 502-398-2462)

Reporting within one business day with EPID 250 (fax (502) 398-2462) and labs with MIC values of:

  • Carbapenem-resistant
  • Acinetobacter
  • Enterobacteriales (Enterobacteriaceae)
  • Pseudomonas
    • Vancomycin-intermediate Staphylococcus aureus (VISA)
    • Vancomycin-resistant Staphylococcus aureus (VRSA)
  • ​Electronic lab reporting within five days is required for (no EPID 250 required):
    • Clostridioides difficile (C. difficile)
    • Enterobacteriales (Enterobacteriaceae) species resistant to ceftazidime, ceftriaxone or cefotaxime  (ESBL)
    • Methicillin-resistant Staphylococcus aureus (MRSA)
    • Vancomycin-resistant Enterococcus species (VRE)

What is an HAI?

HAIs are infections patients develop while receiving healthcare. HAIs can occur in all health settings including, but not limited to, hospitals, ambulatory surgical centers, dialysis facilities, outpatient clinics e.g., physicians' offices, health care clinics , rehabilitation centers and nursing homes. HAIs can be associated with procedures and the devices used in medical care and treatment.

Common HAIs include: central line associated bloodstream infection, catheter-associated urinary tract infection, surgical site infection, Clostridioides difficile and methicillin-resistant Staphylococcus aureus infections.

What is Antimicrobial Resistance?

Antimicrobial/antibiotic resistance occurs when germs like bacteria and fungi have or develop the ability to defeat the drugs designed to kill them. Infections caused by antibiotic-resistant germs are difficult and sometimes impossible, to treat. Consequently, antibiotic-resistant infections can extend hospital stays and require additional follow-up doctor visits and costly, toxic alternative therapies.

Antibiotic resistance does not mean a person is resistant to antibiotics, but, rather, bacteria have become resistant to antibiotics designed to kill them. To survive, germs are constantly finding new defense strategies to survive the effects of antibiotics.

Bacteria develop resistance through traits in their DNA. Often, resistance genes are found in DNA that carry genetic instructions from one germ to another. Some bacteria can share their DNA and make other germs resistant. More in-depth information may be found:

Browse more in-depth information about antibiotic resistance

Regional Infection Preventionists

To better assist in the response to the COVID-19 pandemic, the department recently added regional infection preventionists. These regional IPs work with facilities in the local communities to help respond to and control the spread of COVID-19 in the health care setting.

Kentucky is divided into 10 regions, each with a regional infection preventionist. See map and table below for contact information. ​

HAI K-RIP Regional Map

Region Name and email link Title Work Cell
N/A Mary Fister
Admin SpecialistN/A
N/A
Ruth BelflowerRegional IP Coordinator(502) 871-2628
1 Pat LewisRegional IP(502) 871-2350
2
Lana Newkirk
Regional IP(502) 871-2632
3Holly Swift
Regional IP(502) 395-8440
4 Betty Prochaska
Regional IP(502) 871-2625
5 Jennie LongRegional IP(502) 871-2349
6 Mattheus SmitRegional IP(502) 871-2631
7 Komal GurjarRegional IP(502) 871-2347
8 Cheryl HooperRegional IP(502) 871-2627
9 Naomi WilliamsRegional IP(502) 871-2630
10 Linda SmitRegional IP
(502) 871-2629

Kentucky State-Regional Infection Prevention and Epidemiology

Kentucky-State Regional Infection Prevention and Epidemiology advises the HAI/AR Prevention Program. Kentucky Hospital Association is a long-term partner of the HAI/AR Prevention Program, working on issues of infection prevention and control in acute care and critical access hospitals and providing education to infection preventionists in Kentucky. 

More information about the program can be found in the State HAI Plan .

MDRO

Multi-drug resistant organisms MDROs are common germs, usually bacteria, resistant to multiple antibiotics. MDROs can cause active infections with or without symptoms.

MDROs commonly spread by direct contact between people or with contaminated surfaces in the environment. MDROs can be difficult to treat, depending on the antibiotics to which the bacteria are resistant.

MDRO Reporting

MDRO reporting has been required since 2016 and involves completing the multidrug-resistant reporting formEPID 250​ (fillab​le form: EPID  250 Fillable) and providing the associated laboratory results. Instructions for filling out the EPID 250 are provided, as are more in-depth definitions for carbapenem-resistant organisms.

The MDRO Reporting mandate has been updated. Please see updated version above.

New Recognized Infectious Agents, HAI Outbreaks, Emerging Pathogens and Pathogens of Public Health Importance

An outbreak of a disease or condition that resulted in multiple hospitalizations or death is expected to be reported immediately by phone to the Kentucky Department for Public Health.

An unexpected pattern of cases, suspected cases or deaths which may indicate a newly-recognized infectious agent; an outbreak or epidemic; an emerging pathogen posing a public health danger; or a non-infectious chemical, biological or radiological agent. These events are to be reported to the Kentucky Department for Public Health by phone.

Outbreaks and Investigations

As reports are processed the HAI/AR Prevention Program will conduct outbreak investigations when indicated. An HAI outbreak is defined as: the occurrence of two or more HAIs or MDROs epidemiologically linked or connected by person, place or time; or a single case of an HAI not commonly diagnosed. An investigation also may occur if a specific HAI or MDRO is found in a location for the first time.

Response

Investigations are traditionally focused on outbreaks of MDROs and emerging pathogens. Additionally, there have been investigations related to infections occurring related to devices e.g., intrathecal pain pumps and outpatient procedures intra-articular joint injections. Site visits are conducted when possible. We engage CDC when emerging pathogens/mechanisms are identified. We use the Kentucky Division of Laboratory Services and CDC lab for pulsed field gel electrophoresis and whole-genome sequencing when needed.

Point Prevalence Survey

A point prevalence survey (PPS) involves screening at-risk individuals when there is concern for potential horizontal transmission of MDROs between patients either directly or via healthcare providers. The Antibiotic Resistance Laboratory Network provides assistance when PPS are performed. The AR Lab Network national initiative is funded through CDC grants.

If within-facility transmission is identified or suspected, PPS will continue until transmission is halted. Additionally, a targeted onsite assessment will be performed if possible and assistance provided to the facility to mitigate breaches of infection prevention and control. Re-emphasis on facility infection prevention and control activities always is part of the response.

Target Infections Control Assessment and Response

Infection Control Assessment Tools were developed by CDC under the Epidemiology and Laboratory Capacity Infection Control Assessment and Response Program to help health departments assess infection prevention practices and guide quality improvement activities, such as addressing identified gaps. These tools also may be used by health care facilities to conduct internal quality improvement audits.

NHSN

What is NHSN?

The CDC National Healthcare Safety Network is a national HAI tracking system that provides data to identify problem areas, measure progress of prevention efforts and ultimately eliminate health care-associated infections.

The network allows health care facilities to track HAIs as well as blood safety errors and important health care process measures such as healthcare personnel influenza vaccine status and infection control adherence rates.

Target, Assess and Prevent

The Targeted Assessment for Prevention (TAP) Strategy is a framework for quality improvement developed by the CDC to use data for action to prevent HAIs. The TAP Strategy consists of three components: 1. running TAP reports in the National Healthcare Safety Network (NHSN) to target healthcare facilities and specific units with an excess burden of HAIs; 2. administering TAP facility assessment tools to identify gaps in infection prevention in the targeted locations; and 3. accessing infection prevention resources in TAP implementation guides to address those gaps. The TAP assessment survey is administered to a variety of people in the hospital to identify breaches in knowledge for specific infection control practices and activities.

The Statewide Annual TAP Report is available for the years 2015-2017 and the year 2018-2020 is expected September 2021 .

Extensively Drug Resistant Organism Registry

The XDRO registry is populated with patient information and laboratory data for all carbapenem-resistant Enterobacteriaceae CRE identified in Kentucky facilities or identified in Kentucky residents. The registry can be queried by facility infection preventionists to support appropriate transmission-based precautions when patients have healthcare contact. Initial entry in the XDRO registry is made manually by the HAI/AR Prevention Program staff, although eventually the registry will be populated automatically from electronic laboratory reporting through the Kentucky Health Information Exchange (KHIE) . Additionally, an alert feature is planned to allow real-time use of admission, transfer and discharge data in KHIE to alert facilities of patient CRE history. This will provide more timely initiation of appropriate transmission-based precautions and limit opportunities for spread of the organism in the facility.

If you are interested in gaining access to the database please contact Brittany Corley.

Antimicrobial Stewardship

According to SHEA , antibiotic stewardship involves coordinated strategies to improve use of antimicrobial medications to enhance patient health outcomes, reduce resistance to antibiotics and decrease unnecessary costs.

Antimicrobial stewardship includes a systematic effort to educate and persuade prescribers of antimicrobials to follow evidence-based prescribing.

Statewide antimicrobial stewardship report 2013-14

Collaborative

Activities

  • The Louisville-Metropolitan Antimicrobial Resistance/Antibiotic Stewardship Collaborative serves as a vehicle for discussion of issues related to infection prevention and control, antimicrobial resistance and antibiotic stewardship. Participants include physicians, infection preventionists, microbiologists and others from acute and long-term care facilities in the Louisville metropolitan area. Goals include strengthening inter-facility communication and improving consistency of response to antimicrobial resistance threats.
  • Southeastern Kentucky Regional Collaborative brings together healthcare facilities in the region to discuss issues of infection prevention, antibiotic resistance and interfacility communication 
  • Work with Alliant Quality is a quality-improvement group for Alliant Health Solutions.
  • The hospital-onset HO MRSA Bloodstream Infection Collaborative with CDC and Tennessee is an effort to reduce rates of MRSA bacteremia in facilities with historically higher rates through targeted evidence-based interventions.
  • Kentucky Hospital Association is a long-term partner of the HAI/AR Prevention Program, working on issues of infection prevention and control in acute care and critical access hospitals and providing education to infection preventionists in Kentucky. 
  • Work with the Child and Adolescent Health Research Design and Support Unit CAHRDS Antibiotic Team, Department of Pediatrics, University of Louisville School of Medicine. This group analyzes Medicaid prescribing and claims data related to antibiotic prescribing in pediatrics to improve outpatient antibiotic prescribing for pediatric patients across the state. More generally, it actively is involved in increasing public and provider knowledge about antibiotic use and antimicrobial resistance as critical public health issues.

Frequently Asked Questions

What is the difference between an active infection and colonization with an organism?

Active infection indicates an organism (bacteria, virus, etc.) is found in or on the body and is associated with signs and/or symptoms of illness. Colonization indicates that an organism is found in or on the body but is not producing signs or symptoms of illness.

Are contact precautions necessary in long-term care?

According to the CDC place CRE colonized or infected residents that are high-risk for transmission on CP. For patients at lower risk for transmission use precautions based on type of care provided.

Resources

Documentation

Contact Us

Andrea Flinchum, MPH, BSN, RN, CIC, FAPIC
Program Manager
KDPH Division of Epidemiology
Phone:(502) 564-7193

Kevin Spicer, MD, PhD, MPH
Antibiotic Resistance Coordinator
Medical Officer (CDC/DHQP/PRB)
Phone:(502)564-7166

Michael Curran, BSN, RN, NHDP-BC
Infection Prevention Nurse
KDPH Division of Epidemiology
Phone:(502) 564-7186

Chad Eldridge, DNP​, RN
Infection Prevention Nurse
KDPH Division of Epidemiology
Phone:(502) 564-7187

Clay Bryan​t 
NHSN Program Lead​
KDPH Division of Epidemiology
Phone: (502) 564-5088​

Mary Issac, MPH
Epidemiologist
KDPH Division of Epidemiology
Phone:(502) 564-7214

Brittany Corley, PhD, MPH
Epidemiologist
KDPH Division of Epidemiology
Phone:(502) 564-7185​

Ruth Belflower, MPH, RN, CIC, FAPIC
Regional Infection Preventionist Coordinator
KDPH Division of Epidemiology
Phone: (502) 871-2350

Mary R Fister
Program Administrative Assistant
KDPH Division of Epidemiology
Phone:(502) 564-7189

Aravind Pillai, PHD, MBBS, MPH
Epidemiologist
KDPH Division of Epidemiology
Phone: (502) 564-7218




Additional Information